For example, the amplification of BRAF has been observed in dabrafenib and trametinib combination therapy-resistant melanoma and colon cancer patients, with additional variations in BRAF splicing found in the melanoma patients [163,165,166,167]. This evidence concerns the gene BRAF and malignant colon neoplasm.